ID   A2058
AC   CVCL_1059
SY   A 2058; A-2058
DR   BTO; BTO:0002975
DR   CLO; CLO_0001566
DR   EFO; EFO_0006361
DR   CLDB; cl190
DR   CLDB; cl7207
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-11147
DR   BCRC; 60240
DR   BioSample; SAMN01821723
DR   BioSample; SAMN03470825
DR   BioSample; SAMN10988063
DR   Cell_Model_Passport; SIDM00797
DR   CGH-DB; 9291-4
DR   ChEMBL-Cells; CHEMBL3308030
DR   ChEMBL-Targets; CHEMBL613503
DR   Cosmic; 687430
DR   Cosmic; 888986
DR   Cosmic; 890885
DR   Cosmic; 905205
DR   Cosmic; 906792
DR   Cosmic; 928750
DR   Cosmic; 1022284
DR   Cosmic; 1028799
DR   Cosmic; 1054857
DR   Cosmic; 1155286
DR   Cosmic; 1303031
DR   Cosmic; 1477415
DR   Cosmic; 1481414
DR   Cosmic; 1507608
DR   Cosmic; 1669119
DR   Cosmic; 1995329
DR   Cosmic; 2159438
DR   Cosmic; 2233659
DR   Cosmic; 2651881
DR   Cosmic-CLP; 906792
DR   DepMap; ACH-000788
DR   eagle-i;
DR   ECACC; 91100402
DR   GDSC; 906792
DR   GEO; GSM162906
DR   GEO; GSM206442
DR   GEO; GSM274680
DR   GEO; GSM276736
DR   GEO; GSM827157
DR   GEO; GSM887916
DR   GEO; GSM1138786
DR   GEO; GSM1374379
DR   GEO; GSM1669579
DR   IARC_TP53; 21159
DR   ICLC; HTL08002
DR   JCRB; IFO50276
DR   LiGeA; CCLE_398
DR   Lonza; 999
DR   PharmacoDB; A2058_38_2019
DR   Progenetix; CVCL_1059
DR   Wikidata; Q54606435
RX   PubMed=2203689;
RX   PubMed=6254071;
RX   PubMed=7520026;
RX   PubMed=8980186;
RX   PubMed=9354451;
RX   PubMed=9466661;
RX   PubMed=11448059;
RX   PubMed=12068308;
RX   PubMed=14692828;
RX   PubMed=15048078;
RX   PubMed=15467732;
RX   PubMed=17308088;
RX   PubMed=17516929;
RX   PubMed=19147755;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=23285177;
RX   PubMed=24576830;
RX   PubMed=24581590;
RX   PubMed=25485619;
RX   PubMed=25960936;
RX   PubMed=25984343;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
CC   Part of: BRAF genetic alteration cell panel (ATCC TCP-1032).
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Doubling time: 27 hours (PubMed=25984343).
CC   HLA typing: A*03:01,25:01; B*07:02,35:08; C*07:02,07:02; DQA1*01:02,02:01; DQB1*06:02,06:02; DRB1*15:01,14:10 (PubMed=25960936).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; PubMed=15048078; PubMed=15467732; PubMed=24576830; ATCC; CCLE; Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Homozygous (CCLE; Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 15979; TP63; Simple; p.Arg379Cys (c.1135C>T); Zygosity=Heterozygous (CCLE; Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0%; Native American=0.45%; East Asian, North=0.51%; East Asian, South=0%; South Asian=0.49%; European, North=71.7%; European, South=26.84% (PubMed=30894373).
CC   Misspelling: A2658; In CGH-DB 9291-4.
CC   Derived from metastatic site: Lymph node.
ST   Source(s): ATCC; Cosmic-CLP; Genomics_Center_Technion_BCF; JCRB; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D10S1248: 14,15
ST   D12S391: 22,23
ST   D13S317: 13,14
ST   D16S539: 9,13
ST   D18S51: 13,15
ST   D19S433: 14
ST   D1S1656: 15,18.3
ST   D21S11: 29,30.2
ST   D22S1045: 16,17,18
ST   D2S1338: 17,18
ST   D2S441: 11.3,14
ST   D3S1358: 14,15
ST   D5S818: 9,12
ST   D7S820: 11
ST   D8S1179: 12,13
ST   DYS391: 11
ST   FGA: 21,24
ST   Penta D: 9,12
ST   Penta E: 10,13
ST   TH01: 7,9
ST   TPOX: 8
ST   vWA: 14,18
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   43Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 20-05-21; Version: 36
RX   PubMed=2203689; DOI=10.1002/ijc.2910460322;
RA   Ladanyi A., Timar J., Paku S., Molnar G., Lapis K.;
RT   "Selection and characterization of human melanoma lines with different
RT   liver-colonizing capacity.";
RL   Int. J. Cancer 46:456-461(1990).
RX   PubMed=6254071; DOI=10.1073/pnas.77.9.5258;
RA   Todaro G.J., Fryling C., De Larco J.E.;
RT   "Transforming growth factors produced by certain human tumor cells:
RT   polypeptides that interact with epidermal growth factor receptors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 77:5258-5262(1980).
RX   PubMed=7520026; DOI=10.1002/ijc.2910580413;
RA   Hersey P., Si Z., Smith M.J., Thomas W.D.;
RT   "Expression of the co-stimulatory molecule B7 on melanoma cells.";
RL   Int. J. Cancer 58:527-532(1994).
RX   PubMed=8980186; DOI=10.1002/(SICI)1097-0215(19961211)68:6<795::AID-IJC18>3.0.CO;2-#;
RA   Thomas W.D., Smith M.J., Si Z., Hersey P.;
RT   "Expression of the co-stimulatory molecule CD40 on melanoma cells.";
RL   Int. J. Cancer 68:795-801(1996).
RX   PubMed=9354451;
RA   Castellano M., Pollock P.M., Walters M.K., Sparrow L.E., Down L.M.,
RA   Gabrielli B.G., Parsons P.G., Hayward N.K.;
RT   "CDKN2A/p16 is inactivated in most melanoma cell lines.";
RL   Cancer Res. 57:4868-4875(1997).
RX   PubMed=9466661; DOI=10.1002/(SICI)1097-0215(19980209)75:4<590::AID-IJC16>3.0.CO;2-D;
RA   White C.A., Thomson S.A., Cooper L., van Endert P.M., Tampe R.,
RA   Coupar B., Qiu L., Parsons P.G., Moss D.J., Khanna R.;
RT   "Constitutive transduction of peptide transporter and HLA genes
RT   restores antigen processing function and cytotoxic T cell-mediated
RT   immune recognition of human melanoma cells.";
RL   Int. J. Cancer 75:590-595(1998).
RX   PubMed=11448059; DOI=10.1023/A:1011043412634;
RA   Adam Z., Adany R., Ladanyi A., Timar J., Balazs M.;
RT   "Liver metastatic ability of human melanoma cell line is associated
RT   with losses of chromosomes 4, 9p21-pter and 10p.";
RL   Clin. Exp. Metastasis 18:295-302(2000).
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
RX   PubMed=14692828; DOI=10.1290/1543-706X(2004)40<35:COHMCL>2.0.CO;2;
RA   Quinones L.G., Garcia-Castro I.;
RT   "Characterization of human melanoma cell lines according to their
RT   migratory properties in vitro.";
RL   In Vitro Cell. Dev. Biol. Anim. 40:35-42(2004).
RX   PubMed=15048078; DOI=10.1038/sj.onc.1207563;
RA   Pavey S., Johansson P., Packer L., Taylor J., Stark M., Pollock P.M.,
RA   Walker G.J., Boyle G.M., Harper U., Cozzi S.-J., Hansen K., Yudt L.,
RA   Schmidt C., Hersey P., Ellem K.A.O., O'Rourke M.G.E., Parsons P.G.,
RA   Meltzer P.S., Ringner M., Hayward N.K.;
RT   "Microarray expression profiling in melanoma reveals a BRAF mutation
RT   signature.";
RL   Oncogene 23:4060-4067(2004).
RX   PubMed=15467732; DOI=10.1038/sj.onc.1208152;
RA   Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J.,
RA   Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.;
RT   "Involvement of overexpressed wild-type BRAF in the growth of
RT   malignant melanoma cell lines.";
RL   Oncogene 23:8796-8804(2004).
RX   PubMed=17308088; DOI=10.1158/0008-5472.CAN-06-3311;
RA   Shields J.M., Thomas N.E., Cregger M., Berger A.J., Leslie M.,
RA   Torrice C., Hao H., Penland S., Arbiser J.L., Scott G., Zhou T.,
RA   Bar-Eli M., Bear J.E., Der C.J., Kaufmann W.K., Rimm D.L.,
RA   Sharpless N.E.;
RT   "Lack of extracellular signal-regulated kinase mitogen-activated
RT   protein kinase signaling shows a new type of melanoma.";
RL   Cancer Res. 67:1502-1512(2007).
RX   PubMed=17516929; DOI=10.1111/j.1600-0749.2007.00375.x;
RA   Johansson P., Pavey S., Hayward N.;
RT   "Confirmation of a BRAF mutation-associated gene expression signature
RT   in melanoma.";
RL   Pigment Cell Res. 20:216-221(2007).
RX   PubMed=19147755; DOI=10.1158/1078-0432.CCR-08-1916;
RA   Augustine C.K., Yoo J.S., Potti A., Yoshimoto Y., Zipfel P.A.,
RA   Friedman H.S., Nevins J.R., Ali-Osman F., Tyler D.S.;
RT   "Genomic and molecular profiling predicts response to temozolomide in
RT   melanoma.";
RL   Clin. Cancer Res. 15:502-510(2009).
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
RX   PubMed=23285177; DOI=10.1371/journal.pone.0052760;
RA   Schayowitz A., Bertenshaw G., Jeffries E., Schatz T., Cotton J.,
RA   Villanueva J., Herlyn M., Krepler C., Vultur A., Xu W., Yu G.H.,
RA   Schuchter L.M., Clark D.P.;
RT   "Functional profiling of live melanoma samples using a novel automated
RT   platform.";
RL   PLoS ONE 7:E52760-E52760(2012).
RX   PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625;
RA   Nissan M.H., Pratilas C.A., Jones A.M., Ramirez R., Won H., Liu C.,
RA   Tiwari S., Kong L., Hanrahan A.J., Yao Z., Merghoub T., Ribas A.,
RA   Chapman P.B., Yaeger R., Taylor B.S., Schultz N., Berger M.F.,
RA   Rosen N., Solit D.B.;
RT   "Loss of NF1 in cutaneous melanoma is associated with RAS activation
RT   and MEK dependence.";
RL   Cancer Res. 74:2340-2350(2014).
RX   PubMed=24581590; DOI=10.1016/j.jdermsci.2014.01.006;
RA   Gehrke S., Otsuka A., Huber R., Meier B., Kistowska M., Fenini G.,
RA   Cheng P., Dummer R., Kerl K., Contassot E., French L.E.;
RT   "Metastatic melanoma cell lines do not secrete IL-1beta but promote
RT   IL-1beta production from macrophages.";
RL   J. Dermatol. Sci. 74:167-169(2014).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K.,
RA   Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).